64 Works

Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Abstract Background Cefoxitin is active against some extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE), but has not been evaluated so far in the intensive care unit (ICU) settings. Data upon its pharmacokinetics (PK), tolerance and efficacy in critical conditions are scanty. We performed a retrospective single-center study in a university hospital medical ICU, in subjects presenting with cefoxitin-susceptible ESBL-PE infection and treated with cefoxitin. The primary aim was to determine cefoxitin PK. Secondary endpoints were efficacy, tolerance, and...

Association of early dexamethasone therapy with mortality in critically Ill COVID-19 patients: a French multicenter study

Matthieu Raymond, Aurélie Le Thuaut, Pierre Asfar, Cédric Darreau, Florian Reizine, Gwenhaël Colin, Charly Dano, Julien Lorber, Baptiste Hourmant, Agathe Delbove, Aurélien Frérou, Jean Morin, Pierre Yves Egreteau, Philippe Seguin, Jean Reignier, Jean-Baptiste Lascarrou & Emmanuel Canet
Abstract Background Dexamethasone is recommended for COVID-19 patients who require oxygen therapy. However, its effectiveness in reducing mortality and intubation, and its safety, remain debated. We aimed to investigate whether dexamethasone reduces day-28 mortality in unselected patients with critical COVID-19. Methods We performed an observational cohort study in consecutive COVID-19 patients admitted to any of 13 French intensive care units (ICUs) in 2020. The primary objective was to determine whether early dexamethasone therapy was associated...

Additional file 3 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 3: Figure S1. Model prediction versus observed cefoxitin concentrations.

Additional file 4 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 4: Figure S2. Visual predictive check obtained with the final model.

Additional file 2 of Association between in-ICU red blood cells transfusion and 1-year mortality in ICU survivors

Alice Blet, Joel B. McNeil, Julie Josse, Bernard Cholley, Raphaël Cinotti, Gad Cotter, Agnès Dauvergne, Beth Davison, Kévin Duarte, Jacques Duranteau, Marie-Céline Fournier, Etienne Gayat, Samir Jaber, Sigismond Lasocki, Thomas Merkling, Katell Peoc’h, Imke Mayer, Malha Sadoune, Pierre-François Laterre, Romain Sonneville, Lorraine Ware, Alexandre Mebazaa & Antoine Kimmoun
Additional file 2: Supplemental Text.

Additional file 3 of Atypical working hours are associated with tobacco, cannabis and alcohol use: longitudinal analyses from the CONSTANCES cohort

Nadine Hamieh, Guillaume Airagnes, Alexis Descatha, Marcel Goldberg, Frédéric Limosin, Yves Roquelaure, Cédric Lemogne, Marie Zins & Joane Matta
Additional file 3: Supplementary Table S3. Baseline characteristics of the employees by indicators of atypical working hours in men between 2012-2017.

Additional file 4 of Atypical working hours are associated with tobacco, cannabis and alcohol use: longitudinal analyses from the CONSTANCES cohort

Nadine Hamieh, Guillaume Airagnes, Alexis Descatha, Marcel Goldberg, Frédéric Limosin, Yves Roquelaure, Cédric Lemogne, Marie Zins & Joane Matta
Additional file 4: Supplementary Table S4. Baseline characteristics of the employees by indicators of atypical working hours in women between 2012-2017.

Atypical working hours are associated with tobacco, cannabis and alcohol use: longitudinal analyses from the CONSTANCES cohort

Nadine Hamieh, Guillaume Airagnes, Alexis Descatha, Marcel Goldberg, Frédéric Limosin, Yves Roquelaure, Cédric Lemogne, Marie Zins & Joane Matta
Abstract Background This study examined prospective associations between atypical working hours with subsequent tobacco, cannabis and alcohol use as well as sugar and fat consumption. Methods In the French population-based CONSTANCES cohort, 47,288 men and 53,324 women currently employed included between 2012 and 2017 were annually followed for tobacco and cannabis use. Among them, 35,647 men and 39,767 women included between 2012 and 2016 were also followed for alcohol and sugar and fat consumption. Three...

Additional file 4 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 4: Figure S2. Visual predictive check obtained with the final model.

Additional file 5 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 5: Figure S3. Probability of target attainment for various cefoxitin doses in patients with CCRIBW = 100 ml/min.

Additional file 6 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 6: Figure S4. Probability of target attainment for different levels of renal function with a cefoxitin dose of 6g/day.

Additional file 1 of Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy

F. Eichler, Caroline Sevin, M. Barth, F. Pang, K. Howie, M. Walz, A. Wilds, C. Calcagni, C. Chanson & L. Campbell
Additional file 1. Verbatims from qualitative interviews with study participants.

Additional file 1 of Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy

F. Eichler, Caroline Sevin, M. Barth, F. Pang, K. Howie, M. Walz, A. Wilds, C. Calcagni, C. Chanson & L. Campbell
Additional file 1. Verbatims from qualitative interviews with study participants.

Additional file 1 of Sufentanil sublingual tablet system for enhanced recovery after total knee arthroplasty: a prospective observational case study

Emmanuel Rineau, Benjamin Dumartinet, Emmanuel Samson, Apolline Dollfus, Corentin Aubourg & Sigismond Lasocki
Additional file 1: Table S1. Postoperative data related to pain and mobilization in patients operated on under general anesthesia.

Sufentanil sublingual tablet system for enhanced recovery after total knee arthroplasty: a prospective observational case study

Emmanuel Rineau, Benjamin Dumartinet, Emmanuel Samson, Apolline Dollfus, Corentin Aubourg & Sigismond Lasocki
Abstract Background Postoperative pain is one of the main factors that delays recovery after prosthetic knee surgery. The use of sufentanil sublingual tablet systems (SSTS) can effectively relieve postoperative pain, but their value in facilitating early mobilization has been little studied so far. Our aim here was to assess whether their use could facilitate recovery after knee arthroplasty in an enhanced recovery program. Case presentation In a prospective observational single-center study, thirty patients operated on...

Additional file 1 of Atypical working hours are associated with tobacco, cannabis and alcohol use: longitudinal analyses from the CONSTANCES cohort

Nadine Hamieh, Guillaume Airagnes, Alexis Descatha, Marcel Goldberg, Frédéric Limosin, Yves Roquelaure, Cédric Lemogne, Marie Zins & Joane Matta
Additional file 1: Supplementary Table S1. The distribution of employees by periods of follow-up.

Additional file 2 of Atypical working hours are associated with tobacco, cannabis and alcohol use: longitudinal analyses from the CONSTANCES cohort

Nadine Hamieh, Guillaume Airagnes, Alexis Descatha, Marcel Goldberg, Frédéric Limosin, Yves Roquelaure, Cédric Lemogne, Marie Zins & Joane Matta
Additional file 2: Supplementary Table S2. The principal component analysis of the qualitative food frequency questionnaire using the Varimax rotation.

Additional file 2 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 2: Table S2. Population PK parameters of cefoxitin.

Additional file 2 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 2: Table S2. Population PK parameters of cefoxitin.

Additional file 3 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 3: Figure S1. Model prediction versus observed cefoxitin concentrations.

Additional file 7 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 7: Table S3. Univariate factors associated with cefoxitin treatment failure.

Additional file 8 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 8: Table S4. Univariate factors associated with the acquisition of cefoxitin-resistance.

Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Abstract Background Cefoxitin is active against some extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE), but has not been evaluated so far in the intensive care unit (ICU) settings. Data upon its pharmacokinetics (PK), tolerance and efficacy in critical conditions are scanty. We performed a retrospective single-center study in a university hospital medical ICU, in subjects presenting with cefoxitin-susceptible ESBL-PE infection and treated with cefoxitin. The primary aim was to determine cefoxitin PK. Secondary endpoints were efficacy, tolerance, and...

Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy

F. Eichler, Caroline Sevin, M. Barth, F. Pang, K. Howie, M. Walz, A. Wilds, C. Calcagni, C. Chanson & L. Campbell
Abstract Background Metachromatic leukodystrophy (MLD), a relentlessly progressive and ultimately fatal condition, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency of the enzyme arylsulfatase A (ARSA). Historically management has been palliative or supportive care. Hematopoietic stem cell transplantation is poorly effective in early-onset MLD and benefit in late-onset MLD remains controversial. Hematopoietic stem cell gene therapy, Libmeldy (atidarsagene autotemcel), was recently approved by the European Medicines Agency for early-onset MLD. Treatment...

Additional file 1 of Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone

Diana-Alexandra Ertl, Justin Le Lorier, Andreas Gleiss, Séverine Trabado, Candace Bensignor, Christelle Audrain, Volha Zhukouskaya, Régis Coutant, Jugurtha Berkenou, Anya Rothenbuhler, Gabriele Haeusler & Agnès Linglart
Additional file 1: Table S1. Demographic, clinical and biochemical characteristics for group 1 (burosumab only). Median, minimum and maximum for demographic and biochemical parameters.

Registration Year

  • 2023
    4
  • 2022
    60

Resource Types

  • Text
    44
  • Collection
    18
  • Audiovisual
    2

Affiliations

  • Centre Hospitalier Universitaire d'Angers
    64
  • University of Angers
    50
  • Inserm
    48
  • University of Paris
    34
  • University of Paris-Saclay
    26
  • Hôpital Européen Georges-Pompidou
    20
  • Hôpital de la Croix-Rousse
    18
  • Hospices Civils de Lyon
    18
  • University of Lyon System
    18
  • Centre Hospitalier Lyon Sud
    18